Phase 2a Pilot, Open Label, Multicenter, Study of INV-102 Ophthalmic Solution in Subjects With Non-center Involved Diabetic Macular Edema (NCIDME) Associated With Non-proliferative Diabetic Retinopathy (NPDR)
Latest Information Update: 09 Dec 2024
Price :
$35 *
At a glance
- Drugs INV-102-Invirsa (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Sponsors Invirsa
- 03 Dec 2024 Planned End Date changed from 1 Mar 2025 to 1 Aug 2025.
- 03 Dec 2024 Planned primary completion date changed from 1 Mar 2025 to 1 Aug 2025.
- 30 Sep 2024 New trial record